EA013966B1 - Применение эритропоэтина для лечения сахарного диабета - Google Patents

Применение эритропоэтина для лечения сахарного диабета Download PDF

Info

Publication number
EA013966B1
EA013966B1 EA200700196A EA200700196A EA013966B1 EA 013966 B1 EA013966 B1 EA 013966B1 EA 200700196 A EA200700196 A EA 200700196A EA 200700196 A EA200700196 A EA 200700196A EA 013966 B1 EA013966 B1 EA 013966B1
Authority
EA
Eurasian Patent Office
Prior art keywords
erythropoietin
cells
use according
pharmaceutical composition
progenitor cells
Prior art date
Application number
EA200700196A
Other languages
English (en)
Russian (ru)
Other versions
EA200700196A1 (ru
Inventor
Фердинанд Херманн Бальманн
Херманн Халлер
Original Assignee
Эпоплус Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпоплус Гмбх Унд Ко. Кг filed Critical Эпоплус Гмбх Унд Ко. Кг
Publication of EA200700196A1 publication Critical patent/EA200700196A1/ru
Publication of EA013966B1 publication Critical patent/EA013966B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA200700196A 2002-07-26 2003-07-25 Применение эритропоэтина для лечения сахарного диабета EA013966B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10234192A DE10234192B4 (de) 2002-07-26 2002-07-26 Verwendung von Erythropoetin

Publications (2)

Publication Number Publication Date
EA200700196A1 EA200700196A1 (ru) 2007-04-27
EA013966B1 true EA013966B1 (ru) 2010-08-30

Family

ID=30128436

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200500281A EA009463B1 (ru) 2002-07-26 2003-07-25 Применение эритропоэтина
EA200801236A EA200801236A1 (ru) 2002-07-26 2003-07-25 Применение эритропоэтина
EA200700196A EA013966B1 (ru) 2002-07-26 2003-07-25 Применение эритропоэтина для лечения сахарного диабета

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA200500281A EA009463B1 (ru) 2002-07-26 2003-07-25 Применение эритропоэтина
EA200801236A EA200801236A1 (ru) 2002-07-26 2003-07-25 Применение эритропоэтина

Country Status (27)

Country Link
US (4) US7745387B2 (pt)
EP (3) EP1779862B1 (pt)
JP (4) JP4727988B2 (pt)
KR (2) KR20050026513A (pt)
CN (3) CN1681526A (pt)
AT (2) ATE468132T1 (pt)
AU (2) AU2003255290B2 (pt)
BR (1) BR0312981A (pt)
CA (2) CA2710100A1 (pt)
CY (2) CY1108052T1 (pt)
DE (3) DE10234192B4 (pt)
DK (2) DK1526867T3 (pt)
EA (3) EA009463B1 (pt)
ES (2) ES2345673T3 (pt)
HK (2) HK1081841A1 (pt)
HR (3) HRP20050065A2 (pt)
IL (2) IL166401A0 (pt)
IS (3) IS2671B (pt)
MX (1) MXPA05001120A (pt)
NO (1) NO20051002L (pt)
PL (2) PL374874A1 (pt)
PT (2) PT1526867E (pt)
SG (1) SG177004A1 (pt)
SI (2) SI1526867T1 (pt)
UA (2) UA94913C2 (pt)
WO (1) WO2004012759A2 (pt)
ZA (1) ZA200500726B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
SI1660115T1 (sl) * 2003-07-29 2011-10-28 Dompe Spa Farmacevtska kombinacija G-CSF in PLGF koristna za krvne matične celice
CA2550301A1 (en) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Tissue regeneration method
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
CN101115496B (zh) 2004-12-06 2012-03-07 加州大学评议会 改善微动脉的结构和功能的方法
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1973559B1 (en) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
MX2008015392A (es) * 2006-06-07 2009-05-05 Univ Tokushima Tratamiento de enfermedades isquemicas que usan eritropoyetina.
CA2665037A1 (en) * 2006-09-29 2008-04-10 Centocor Ortho Biotech Inc. Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP3040347A3 (en) * 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2008047914A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
JP5869219B2 (ja) 2007-08-16 2016-02-24 レメドー バイオメッド リミテッド 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP3345921A1 (en) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Use of anti-actriib antibodies for increasing thermogenic adipocytes
ES2836534T3 (es) 2009-06-12 2021-06-25 Acceleron Pharma Inc Proteínas de fusión de ActRIIB-Fc truncadas
EP3838919A1 (en) * 2009-08-13 2021-06-23 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
ES2632164T3 (es) 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
WO2012148200A2 (ko) * 2011-04-26 2012-11-01 아주대학교 산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
CN104936605A (zh) 2012-11-02 2015-09-23 细胞基因公司 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
JP6220969B2 (ja) * 2013-10-22 2017-10-25 コンシーヴァルブ エルエルシー ステント装着した心臓弁または生体補綴弁の狭窄、閉塞、または石灰化を阻害するための方法
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
US11534466B2 (en) * 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
JP2019528284A (ja) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
CN108114282B (zh) * 2016-11-28 2021-03-02 北京大学第三医院 他汀类化合物治疗缺血性疾病的用途
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
KR20200074160A (ko) * 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
RU2695334C1 (ru) * 2018-09-25 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте
RU2678768C1 (ru) * 2018-09-25 2019-02-01 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007944A1 (en) * 1988-02-24 1989-09-08 American National Red Cross Device for site directed neovascularization and method for same
US4992419A (en) * 1987-05-09 1991-02-12 Boehringer Mannheim Gmbh Stabilized erythropoietin preparations
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
US5198417A (en) * 1985-11-27 1993-03-30 Genetics Institute, Inc. Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
WO1998010650A1 (en) * 1996-09-11 1998-03-19 East Carolina University Method of treating endothelial injury
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO2000061164A1 (en) * 1999-04-13 2000-10-19 Kenneth S. Warren Laboratories Modulation of excitable tissue function by peripherally administered erythropoietin
WO2002014356A2 (en) * 2000-08-11 2002-02-21 Baxter Healthcare Sa Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) * 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
WO2002085940A2 (en) * 2001-04-04 2002-10-31 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
WO2003037273A2 (en) * 2001-11-01 2003-05-08 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
WO2003057242A1 (en) * 2002-01-09 2003-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3686582T2 (de) 1985-11-27 1993-01-28 Genetics Inst Behandlung einer krankheit vom aids-typ.
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5013718A (en) 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
DE4014654A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994025055A1 (en) 1993-04-29 1994-11-10 Abbott Laboratories Erythropoietin analog compositions and methods
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
DE69531952T2 (de) 1994-11-03 2004-07-29 Roche Diagnostics Gmbh Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US6284260B1 (en) 1998-02-04 2001-09-04 Veronica L. Zaharia Czeizler Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters
US6274158B1 (en) * 1998-02-04 2001-08-14 Veronica L. Zaharia Czeizler Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2001082953A2 (en) 2000-05-02 2001-11-08 Action Pharma Aps Methods for treatment of diseases associated with inflammation under non-ischemic conditions
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP2005530678A (ja) * 2001-11-28 2005-10-13 オーソーマクニール ファーマシューティカル， インコーポレイテッド 貧血治療用のエリスロポエチン投与療法
US6748154B2 (en) * 2002-03-28 2004-06-08 Nortel Networks Limited Optical module access tray
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198417A (en) * 1985-11-27 1993-03-30 Genetics Institute, Inc. Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
US4992419A (en) * 1987-05-09 1991-02-12 Boehringer Mannheim Gmbh Stabilized erythropoietin preparations
WO1989007944A1 (en) * 1988-02-24 1989-09-08 American National Red Cross Device for site directed neovascularization and method for same
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
WO1998010650A1 (en) * 1996-09-11 1998-03-19 East Carolina University Method of treating endothelial injury
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO2000061164A1 (en) * 1999-04-13 2000-10-19 Kenneth S. Warren Laboratories Modulation of excitable tissue function by peripherally administered erythropoietin
WO2002014356A2 (en) * 2000-08-11 2002-02-21 Baxter Healthcare Sa Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) * 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
WO2002085940A2 (en) * 2001-04-04 2002-10-31 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
WO2003037273A2 (en) * 2001-11-01 2003-05-08 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
WO2003057242A1 (en) * 2002-01-09 2003-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BLOOD, Bd. 98, Nr. 11, Part 1, 16. November 2001 (2001-11-16), Seiten 822a-823a, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, ISSN: 0006-4971 *
BUEMI M. ET AL.: "Recombinant erythropoietin prevents the progression of atherosclerosis in Watanabe rabbits with hereditary hypocholesterolemia", NEPHROLOGY DIALYSIS TRANSPLANTATION, Bd. 12, Nr. 9, 1997, Seite A190, XP009021639 & ANNUAL CONGRESS OF THE EUROPEAN RENAL ASSOCIATION AND THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATI; GENEVA, SWITZERLAND; SEPTEMBER 21-24, 1997, ISSN: 0931-0509, Zusammenfassung *
BUEMI M. ET AL.: "Recombinant human erythropoietin (rHuEPO): More than just the correction of uremic anemia", JOURNAL OF NEPHROLOGY 2002 ITALY, Bd. 15, Nr. 2, 2002, Seiten 97-103, XP009021789, ISSN: 1121-8428, Seite 99, Spalte 1, Seite 101, Spalte 1, Seite 101, Spalte 2 *
DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16. November 2001 (2001-11-16), ARCASOY MURAT O. ET AL.: "Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing", XP002275417, Database accession no. PREV200200261552, Zusammenfassung *
DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CONRAD KIRK P. ET AL.: "Placental cytokines and the pathogenesis of preeclampsia", XP002275414, Database accession no. PREV199799525116, Zusammenfassung & AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, Bd. 37, Nr. 3, 1997, Seiten 240-249, ISSN: 1046-7408 *
DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1998 (1998-11), ALVAREZ ARROYO MARIA VICTORIA ET AL.: "Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation", XP002275418, Database accession no. PREV199800506855, Zusammenfassung & JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, Bd. 9, Nr. 11, November 1998 (1998-11), Seiten 1998-2004, ISSN: 1046-6673 *
DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2000, CASES A: "Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature", XP002275415, Database accession no. EMB-2000364537, Zusammenfassung & DRUGS OF TODAY 2000 SPAIN, Bd. 36, Nr. 8, 2000, Seiten 541-556, ISSN: 0025-7656 *
DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; Mai 1996 (1996-05), BRAGA J. ET AL.: "Maternal and perinatal implications of the use of human recombinant erythropoietin", XP002275416, Database accession no. NLM8677769, Zusammenfassung & ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. MAY 1996, Bd. 75, Nr. 5, Mai 1996 (1996-05), Seiten 449-3, ISSN: 0001-6349 *
KRAUSE K. ET AL.: "Recombinant human erythropoietin and VEGF have equal angiogenic potency: Investigation in a novel in vitro assay of human vascular tissues", EUROPEAN HEART JOURNAL, Bd. 22, Nr. Abstract Supplement, September 2001 (2001-09), Seite 154, XP001097312 & XXIII CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY TOGETHER WITH THE 36TH ANNUAL GENERAL MEETING O; STOCKHOLM, SWEDEN; SEPTEMBER 01-05, 2001, ISSN: 0195-668X, Zusammenfassung *
MASCHIO G.: "Erythropoietin and systemic hypertension", NEPHROLOGY DIALYSIS TRANSPLANTATION, Bd. 10, Nr. SUPPL. 2, 1995, Seiten 74-79, XP009021640 & ISSN: 0931-0509, Zusammenfassung *
MASUDA SEIJI ET AL.: "Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production", INTERNATIONAL JOURNAL OF HEMATOLOGY, Bd. 70, Nr. 1, Juli 1999 (1999-07), Seiten 1-6, XP009021621 & ISSN: 0925-5710, Seite 3, Spalte 2, Absatz 3 - Seite 4, Spalte 1, Absatz 3; Abbildung 1 *

Also Published As

Publication number Publication date
WO2004012759B1 (de) 2004-07-08
DK1526867T3 (da) 2007-09-17
IS8909A (is) 2010-07-02
HK1081841A1 (en) 2006-05-26
BR0312981A (pt) 2005-06-14
EA200500281A1 (ru) 2005-06-30
NO20051002L (no) 2005-04-18
SI1779862T1 (sl) 2010-09-30
PT1526867E (pt) 2007-07-09
US20100247452A1 (en) 2010-09-30
AU2003255290B2 (en) 2009-04-09
ES2285195T3 (es) 2007-11-16
EP1526867B1 (de) 2007-04-25
CN101099860A (zh) 2008-01-09
CA2493598A1 (en) 2004-02-12
US20100247451A1 (en) 2010-09-30
CN101099860B (zh) 2011-06-01
EP1779862B1 (de) 2010-05-19
ATE468132T1 (de) 2010-06-15
CN1681526A (zh) 2005-10-12
IS8817A (is) 2009-05-06
EA200700196A1 (ru) 2007-04-27
JP2006503001A (ja) 2006-01-26
DE50312729D1 (de) 2010-07-01
EP1779862A1 (de) 2007-05-02
CY1110713T1 (el) 2015-06-10
EA009463B1 (ru) 2007-12-28
ZA200500726B (en) 2006-06-28
DE50307140D1 (en) 2007-06-06
PT1779862E (pt) 2010-08-18
JP2010280671A (ja) 2010-12-16
UA85997C2 (en) 2009-03-25
SI1526867T1 (sl) 2007-10-31
IS7633A (is) 2005-01-06
WO2004012759A3 (de) 2004-06-03
HK1108625A1 (en) 2008-05-16
KR20050026513A (ko) 2005-03-15
IL166401A0 (en) 2006-01-15
KR20100077033A (ko) 2010-07-06
DE10234192B4 (de) 2009-11-26
HRP20100187A2 (en) 2010-08-31
EP2191838A1 (de) 2010-06-02
HRP20050065A2 (en) 2005-10-31
ES2345673T3 (es) 2010-09-29
EP1526867A2 (de) 2005-05-04
AU2003255290A1 (en) 2004-02-23
WO2004012759A2 (de) 2004-02-12
US20100247450A1 (en) 2010-09-30
PL374874A1 (en) 2005-11-14
UA94913C2 (ru) 2011-06-25
CA2710100A1 (en) 2004-02-12
MXPA05001120A (es) 2005-08-03
DE10234192A1 (de) 2004-02-12
IL204577A (en) 2012-08-30
CN101099731B (zh) 2011-02-16
CY1108052T1 (el) 2013-09-04
AU2009200748A1 (en) 2009-03-19
JP2010280672A (ja) 2010-12-16
US7745387B2 (en) 2010-06-29
DK1779862T3 (da) 2010-08-16
ATE360436T1 (de) 2007-05-15
US20050272634A1 (en) 2005-12-08
CN101099731A (zh) 2008-01-09
HRP20070189A2 (en) 2007-07-31
SG177004A1 (en) 2012-01-30
IS2671B (is) 2010-09-15
PL395151A1 (pl) 2011-08-16
EA200801236A1 (ru) 2009-02-27
JP2010280670A (ja) 2010-12-16
JP4727988B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
EA013966B1 (ru) Применение эритропоэтина для лечения сахарного диабета
AU2005205917B2 (en) Use of low-dose erythropoietin for stimulation of endothelial progenitor cells, for organ regeneration and for slowing the progression of end-organ damage
JP5400006B2 (ja) 虚血性疾患の予防または治療剤
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
AU2003200309B2 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
NZ553426A (en) Use of erythropoietin for treating diabetes mellitus
MXPA06008181A (en) Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU